Journal · 2026-07-18 · 8 min
Evidence maturity: a paper is not a product
Some of these molecules have licences. Some have phase 3 announcements. Some have rodent papers. The listing should say which.
People shop research catalogues as if every peptide were at the same stage. They are not. Avion Now marks that difference on the compound pages, in plain language, and keeps the product page for the container and the stated strength.
An approval belongs to a labelled product
Tirzepatide is the active substance in licensed medicines. Elamipretide, the peptide also called SS-31, received a narrow US accelerated approval in 2025 as Forzinity, for Barth syndrome, in patients at or above a stated weight, on an intermediate endpoint. Those sentences are about specific finished products. A lyophilised vial from a research catalogue is not Forzinity and it is not Mounjaro.
The practical test is boring. Does the box in your hand carry the licensed name, the licensed strength, the licensed device, and a regulator’s market authorisation? If it does not, the paper about the licensed product is background, not a description of your vial.
An announcement is not a licence
Retatrutide is further along than a curiosity and short of an approval. A 2023 phase 2 trial is in the New England Journal of Medicine. In 2026 the sponsor reported more phase 3 topline results and talked about a filing. Topline results are a press statement about a primary endpoint. They are not the paper, and they are not a licence. We say both things, and we do not paste trial doses onto a product card.
Most of the shorter peptides are earlier than that
BPC-157, the TB-500 fragment, AHK-Cu, KPV, MOTS-c, and epithalon live mostly in preclinical or narrowly published work. Kisspeptin-10 and ipamorelin have real human studies and still no approval. Semax and Selank have a regional clinical history that does not convert an unlicensed bottle into the registered product. Of that list, this catalogue currently sells pens for BPC-157 and MOTS-c only.
KLOW fails a more basic test. It is not a molecule. The pen in this catalogue states 80 mg and does not publish a component list.
How we want the pages used
Use a compound page to see the class, the sequence if we are willing to stand behind it, the stage of the evidence, and the limit. Use a product page to see the container and the stated strength. Use a batch record to see one lot. If a page is doing more than that, it has started to sell a use, and that is not the job.